Tenapanor Hydrochloride Patent Expiration
Tenapanor Hydrochloride is used for reducing serum phosphorus levels and treating hyperphosphatemia in adults. It was first introduced by Ardelyx Inc
Tenapanor Hydrochloride Patents
Given below is the list of patents protecting Tenapanor Hydrochloride, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Xphozah | US10272079 | NHE3-binding compounds and methods for inhibiting phosphate transport | Apr 10, 2034 | Ardelyx Inc |
| Xphozah | US10940146 | NHE3-binding compounds and methods for inhibiting phosphate transport | Apr 10, 2034 | Ardelyx Inc |
| Ibsrela | US8541448 | Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders | Aug 01, 2033 | Ardelyx Inc |
| Xphozah | US8541448 | Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders | Aug 01, 2033 | Ardelyx Inc |
| Ibsrela | US9006281 | Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders | May 02, 2030 | Ardelyx Inc |
| Ibsrela | US12016856 | Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders | Dec 30, 2029 | Ardelyx Inc |
| Ibsrela | US8969377 | Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders | Dec 30, 2029 | Ardelyx Inc |
| Ibsrela | US9408840 | Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorder | Dec 30, 2029 | Ardelyx Inc |
| Xphozah | US12016856 | Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders | Dec 30, 2029 | Ardelyx Inc |
| Xphozah | US8969377 | Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders | Dec 30, 2029 | Ardelyx Inc |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Tenapanor Hydrochloride's patents.
Latest Legal Activities on Tenapanor Hydrochloride's Patents
Given below is the list recent legal activities going on the following patents of Tenapanor Hydrochloride.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 4th Yr, Small Entity | 31 Oct, 2022 | US10272079 |
| Patent Issue Date Used in PTA Calculation Critical | 09 Mar, 2021 | US10940146 |
| Recordation of Patent Grant Mailed Critical | 09 Mar, 2021 | US10940146 |
| Email Notification Critical | 18 Feb, 2021 | US10940146 |
| Issue Notification Mailed Critical | 17 Feb, 2021 | US10940146 |
| Dispatch to FDC | 10 Feb, 2021 | US10940146 |
| Email Notification Critical | 07 Jan, 2021 | US10940146 |
| Mail Response to 312 Amendment (PTO-271) Critical | 07 Jan, 2021 | US10940146 |
| Response to Amendment under Rule 312 Critical | 04 Jan, 2021 | US10940146 |
| Application Is Considered Ready for Issue Critical | 31 Dec, 2020 | US10940146 |
Tenapanor Hydrochloride's Family Patents
